Clinical Institute of the Brain, Russia Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2007
NCT00901381
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (1)

porcine brain-derived peptide preparation (cerebrolysin) (1 trial)

Drugs in Phase 3 Trials (3)

cenegermin-bkbj (oxervate) (1 trial)

citicoline (1 trial)

l-alpha-glycerophosphocholine (1 trial)

Drugs in Phase 2 Trials (1)

sargramostim (leukine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Infarction (Phase 4)

Ischemia (Phase 4)

Stroke (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 5